Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.

Cancer medicine - 1 Jan 2020

Hara Yuta, Minami Yushi, Yoshimoto Soshi, Hayashi Natsumi, Yamasaki Akitaka, Ueda Shiho, Masuko Kazue, Masuko Takashi

Abstract excerpt

KRAS mutations are detected in numerous human cancers, but there are few effective drugs for KRAS-mutated cancers. Transporters for amino acids and glucose are highly expressed on cancer cells, possibly to maintain rapid cell growth and metabolism. Alanine-serine-cysteine transporter 2 (ASCT2) is a primary transporter for glutamine in cancer cells. In this study, we developed a novel monoclonal antibody (mAb)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Gene Knockout Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamine

Share to HEK293 Cells

Share to Minor Histocompatibility Antigens

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31709772
DOI: 10.1002/cam4.2689
PMCID: PMC6943164

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.PMID 31709772Read ↗

Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.Semantic proximity Read ↗

Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer TherapySemantic proximity Read ↗

A pan-cancer analysis of SLC1A5 in human cancersSemantic proximity Read ↗

Anti-SLC7A11 monoclonal antibody Inhibits Tumor Progression through a Janus-faced Effect on CD4 + and CD8 + T Cells in Colorectal CancerSemantic proximity Read ↗

Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.Semantic proximity Read ↗

Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cellsSemantic proximity Read ↗

Development of an improved mammalian overexpression method for human CD62L.Semantic proximity Read ↗

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer.Semantic proximity Read ↗

Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation.Semantic proximity Read ↗

Non-Invasive Glutamine PET Reflects Pharmacological Inhibition of BRAFV600E In Vivo.Semantic proximity Read ↗

Claudin-1 enhances chemoresistance of human lung adenocarcinoma A549 cells mediated by forming an amino acid barrierSemantic proximity Read ↗

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.